Drug delivery systems for the topical treatment of cutaneous leishmaniasis

Amphotericin B-Loaded Nanocarriers for Topical Treatment of Cutaneous Leishmaniasis: Development, Characterization, and In Vitro Skin Permeation Studies

(2012)   Journal of Biomedical Nanotechnology

Liposomal systems as drug delivery vehicles for dermal and transdermal applications

(2011) Maria Bernadete Riemma Pierre et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Nanoparticles in dermatology

(2011) Dimitrios Papakostas et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Leishmaniasis chemotherapy—challenges and opportunities

(2011) S.L. Croft et al.   CLINICAL MICROBIOLOGY AND INFECTION

Leishmaniasis: complexity at the host–pathogen interface

(2011) Paul Kaye et al.   NATURE REVIEWS MICROBIOLOGY

Reductions in Skin and Systemic Parasite Burdens as a Combined Effect of Topical Paromomycin and Oral Miltefosine Treatment of Mice Experimentally Infected with Leishmania (Leishmania) amazonensis

(2010) M. G. Aguiar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential Effects of Paromomycin on Ribosomes ofLeishmania mexicanaand Mammalian Cells

(2010) Marisa M. Fernández et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Topical delivery andin vivoantileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis

(2010) Guilherme Carneiro et al.   JOURNAL OF LIPOSOME RESEARCH

Enhanced Absorption through Damaged Skin: An Overview of the in vitro Human Model

(2010) S. Gattu et al.   SKIN PHARMACOLOGY AND PHYSIOLOGY

Effect of Topical Liposomes Containing Paromomycin Sulfate in the Course of Leishmania major Infection in Susceptible BALB/c Mice

(2009) M. R. Jaafari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Amphotericin B and Its New Derivatives – Mode of Action

(2009) M. Baginski et al.   CURRENT DRUG METABOLISM

Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination

(2009) Nawaf Al-Mutairi et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens

(2009) M. G. Aguiar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Miltefosine Promotes IFN- -Dominated Anti-Leishmanial Immune Response

(2009) P. Wadhone et al.   JOURNAL OF IMMUNOLOGY

Disposition of Charged Nanoparticles after Their Topical Application to the Skin

(2009) X. Wu et al.   SKIN PHARMACOLOGY AND PHYSIOLOGY

WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study

(2009) Afif Ben Salah et al.   PLoS Neglected Tropical Diseases

First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony

(2009) Cesar Miranda-Verastegui et al.   PLoS Neglected Tropical Diseases

Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis

(2008) Albert Schriefer et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Liposomes and skin: From drug delivery to model membranes

(2008) G.M. El Maghraby et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

The skin: an indispensable barrier

(2008) Ehrhardt Proksch et al.   EXPERIMENTAL DERMATOLOGY

Treatment of leishmaniasis with miltefosine: 2008 status

(2008) Jonathan (Josh) Berman   Expert Opinion on Drug Metabolism & Toxicology

Paromomycin in the treatment of leishmaniasis

(2008) Shyam Sundar et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Leishmaniasis

(2008) Hubertus Neuber   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Efeito de uma formulação hidrofílica de paromomicina tópica na leishmaniose cutânea em pacientes com contra-indicações de tratamento com antimonial pentavalente

(2008) Aline Marques dos Santos et al.   Revista da Sociedade Brasileira de Medicina Tropical